CAeditome Logo

Home

Download

Statistics

Landscape

Help

Contact
Center for Computational Systems Medicine
Soverview

1. Gene summary of enriched editing regions

Soverview

2. Tumor-specific enriched editing regions

Comparison of enriched editing regions between tumor and normal.

Correlation of enriched editing regions with tumor stages.

Associations of enriched editing regions with cancer survival.

Soverview

3. Enriched editing regions and immune related genes

Soverview

4. Enriched editing regions and immune related splicing

Soverview

5. Enriched editing regions and immune infiltration

Soverview

6. Enriched editing regions and immune gene sets

Correlation of enriched editing regions with epithelial-mesenchymal transition.

Correlations of enriched editing regions with hypoxic.

Associations of enriched editing regions with hallmark gene sets from MSigDB.

Soverview

7. Enriched editing regions and drugs

Correlations between enriched editing regions and drug sensitivity.

Enriched editing regions targeted by drugs from DrugBank database.

Editing gene: TMOD3 (ImmuneEditome ID:29766)

1. Gene summary of enriched editing regions for TMOD3

check button Gene summary
Gene informationGene symbol

TMOD3

Gene ID

29766

GeneSynonymsUTMOD
GeneCytomap

15q21.2

GeneTypeprotein-coding
GeneDescriptiontropomodulin-3|tropomodulin 3 (ubiquitous)|ubiquitous tropomodulin
GeneModificationdate20230518
UniprotIDQ9NYL9;H0YNU8;H0YNJ8
PubMed ID

check buttonUCSC image.
all structure

check buttonLocations of each EERs.
EERENSTENSGGeneNameRegionRepeatdsRNA structure
chr15:51866172-51866440:+ENST00000308580.10ENSG00000138594.11TMOD3intronicAluJr4chr15:51866172-51866440:+.alignment
chr15:51866172-51866440:+ENST00000544199.4ENSG00000138594.11TMOD3intronicAluJr4chr15:51866172-51866440:+.alignment
chr15:51876830-51877650:+ENST00000308580.10ENSG00000138594.11TMOD3intronicL1MEc,AluJr,AluSq4chr15:51876830-51877650:+.alignment
chr15:51876830-51877650:+ENST00000544199.4ENSG00000138594.11TMOD3intronicL1MEc,AluJr,AluSq4chr15:51876830-51877650:+.alignment
chr15:51876830-51877650:+ENST00000560549.4ENSG00000138594.11TMOD3intronicL1MEc,AluJr,AluSq4chr15:51876830-51877650:+.alignment
chr15:51905317-51905806:+ENST00000560725.1ENSG00000138594.11TMOD3ncRNA_intronicAluSx1,AluYb8chr15:51905317-51905806:+.alignment
chr15:51910429-51910566:+ENST00000560725.1ENSG00000138594.11TMOD3ncRNA_intronicAluSzchr15:51910429-51910566:+.alignment
chr15:51912124-51915053:+ENST00000308580.10ENSG00000138594.11TMOD3UTR3AluSp,AluSx1,Tigger4a,AluSq2,AluSz,AluJb,AluJrchr15:51912124-51915053:+.alignment
chr15:51931974-51933639:+ENST00000558714.4ENSG00000138594.11TMOD3ncRNA_intronicAluY,ERVL-B4-int,AluSx1,L1MC4,AluSxchr15:51931974-51933639:+.alignment
chr15:51931974-51933639:+ENST00000559202.1ENSG00000138594.11TMOD3ncRNA_intronicAluY,ERVL-B4-int,AluSx1,L1MC4,AluSxchr15:51931974-51933639:+.alignment
chr15:51931974-51933639:+ENST00000561408.1ENSG00000138594.11TMOD3ncRNA_intronicAluY,ERVL-B4-int,AluSx1,L1MC4,AluSxchr15:51931974-51933639:+.alignment


Top

2. Tumor-specific enriched editing regions for TMOD3


all structure

check buttonComparison of enriched editing regions between tumor and normal.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypePBoxplot
chr15:51912124-51915053:+BRCAEER2.5910e-16image
ENSG00000138594.11,TMOD3BRCAEAG2.1730e-16image
chr15:51912124-51915053:+COADEER2.0618e-10image
ENSG00000138594.11,TMOD3COADEAG1.8492e-10image
chr15:51912124-51915053:+HNSCEER3.8920e-07image
ENSG00000138594.11,TMOD3HNSCEAG5.0119e-07image
chr15:51912124-51915053:+KICHEER4.0160e-05image
ENSG00000138594.11,TMOD3KICHEAG4.0160e-05image
chr15:51912124-51915053:+KIRPEER1.8183e-03image
ENSG00000138594.11,TMOD3KIRPEAG1.8183e-03image
chr15:51912124-51915053:+LIHCEER2.6443e-02image
ENSG00000138594.11,TMOD3LIHCEAG2.6443e-02image
chr15:51912124-51915053:+LUADEER1.5355e-28image
ENSG00000138594.11,TMOD3LUADEAG1.2735e-28image
chr15:51912124-51915053:+LUSCEER7.5597e-31image
ENSG00000138594.11,TMOD3LUSCEAG7.5597e-31image
chr15:51912124-51915053:+PRADEER1.2318e-02image
ENSG00000138594.11,TMOD3PRADEAG1.2182e-02image
chr15:51912124-51915053:+STADEER2.3282e-03image
ENSG00000138594.11,TMOD3STADEAG6.5365e-03image
chr15:51912124-51915053:+UCECEER9.1066e-06image
ENSG00000138594.11,TMOD3UCECEAG1.1081e-05image


Top

check buttonCorrelation of enriched editing regions with tumor stages.
* AnovaP<0.05, Pearson P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes, Path: Pathological stage, Cli: Clinical stage.
* Only shows the most significant correlation result of EERs/EAGs with either pathological stage or clinical stage according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeStageTypeAnovaPPRBoxplot
ENSG00000138594.11,TMOD3BLCAPathEAG2.5512e-025.0133e-030.1424image
chr15:51912124-51915053:+BLCAPathEER2.5208e-025.1389e-030.1420image
ENSG00000138594.11,TMOD3KIRCPathEAG1.1958e-031.0158e-040.1683image
chr15:51912124-51915053:+KIRCPathEER1.1483e-039.9512e-050.1686image


Top

check button Associations of enriched editing regions with cancer survival.
* Pkm<0.05 and Pcox<0.05.
* EER: enriched editing region, EAG: EER-associated genes.
ID_eventscancerTypeIDPkmPcox_continuousHR_continuousKMPlot

Top

3. Enriched editing regions and immune related genes for TMOD3


all structure

check button Enriched editing regions and immune related genes.
* First, the associations between enriched editing regions and genes were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the gene relationships with immune were tested by three analyses: whether the gene is an immune gene (InnateDB、Immport、Immunome、Immunogenetic Related Information Source (IRIS)), whether the gene is associated with immune infiltration and whether the gene is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of genes with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeGenebetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr15:51912124-51915053:+CESCEERENSG00000126709,IFI60.43822.7291e-111.7922e-150.4445imageNAUH;BUD13;DDX3X;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FUS;GTF2F1;HNRNPC;HNRNPM;IGF2BP2;IGF2BP3;NOP56;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;U2AF1;U2AF2;UPF1IFI6T_cells_CD4_memory_restingGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr15:51912124-51915053:+CESCEERENSG00000187608,ISG150.41902.9401e-102.1999e-140.4286imageNAUH;CSTF2T;DDX3X;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;NOP56;NOP58;NUMA1;PRPF8;RANGAP1;RBFOX2;RBM10;SND1;SRSF1;TAF15;TROVE2;U2AF2;UPF1;ZNF184ISG15T_cells_CD4_memory_restingGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr15:51912124-51915053:+CESCEERENSG00000114062,UBE3A-0.39461.2033e-085.3872e-13-0.4070imageNAUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;LARP7;NOP56;NOP58;NUMA1;PRPF8;RANGAP1;RBFOX2;RBM10;RNF219;SLTM;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184UBE3AT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr15:51912124-51915053:+CESCEERENSG00000180979,LRRC57-0.38941.7596e-085.3216e-14-0.4228imageNBUD13;CSTF2T;DDX3X;DDX42;DDX54;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;NOP56;NOP58;NUMA1;PRPF8;RANGAP1;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1;XRN2NAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr15:51912124-51915053:+CESCEERENSG00000165949,IFI270.38202.6058e-081.1216e-140.4329imageNCSTF2T;DGCR8;DKC1;EIF4A3;ELAVL1;FBL;FUS;HNRNPC;HNRNPK;IGF2BP2;NOP56;NOP58;NUMA1;RBFOX2;RBM10;SND1;SRSF1;SRSF9;TAF15;U2AF2;XRN2;ZNF184IFI27T_cells_CD4_memory_restingGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr15:51912124-51915053:+CESCEERENSG00000130303,BST20.37369.6680e-081.2522e-120.4010imageNAUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX42;DGCR8;EIF4A3;FAM120A;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;LARP7;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1;XRN2BST2B_cells_memoryGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr15:51912124-51915053:+CESCEERENSG00000019995,ZRANB1-0.36571.8760e-071.0732e-12-0.4021imageNAUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;LARP7;NOP56;NOP58;NUMA1;PRPF8;RANGAP1;RBFOX2;RBM10;SLTM;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAT_cells_CD4_memory_restingGSVA_HALLMARK_MITOTIC_SPINDLE
chr15:51912124-51915053:+COADEERENSG00000148584,A1CF-0.41023.8245e-083.4161e-12-0.4084imageNBCCIP;BUD13;DDX54;DGCR8;DKC1;ELAVL1;FAM120A;FBL;FUS;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;LARP7;NOP56;NOP58;PRPF8;RBFOX2;SLTM;SND1;SRSF1;SRSF9;TAF15;U2AF2A1CFEosinophilsGSVA_HALLMARK_P53_PATHWAY
chr15:51912124-51915053:+COADEERENSG00000156587,UBE2L60.37159.8529e-073.4620e-120.4082imageNAUH;BUD13;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;LARP7;NOP56;NOP58;PRPF8;RBFOX2;SLTM;SND1;SRSF1;TAF15;TROVE2;U2AF1;U2AF2;UPF1;XRN2NAMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr15:51912124-51915053:+COADEERENSG00000068079,IFI350.35204.0511e-064.3728e-120.4065imageNBCCIP;BUD13;CSTF2T;DDX3X;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;IGF2BP2;IGF2BP3;NOP56;NOP58;PRPF8;RBFOX2;RBM10;SLTM;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1;XRN2IFI35Macrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE

More results



Top

4. Enriched editing regions and immune related splicing for TMOD3


all structure

check button Enriched editing regions and immune related splicing.
* First, the associations between enriched editing regions and splicing events were tested by QTL and Pearson method (QTL: FDR<0.05 and Pearson: P<0.05).
* Second, the splicing relationships with immune were tested by three analyses: whether the splicing event locates in an immune gene (InnateDB、Immport, Immunome and Immunogenetic Related Information Source (IRIS)), whether the splicing event is associated with immune infiltration and whether the splicing event is related to immune gene sets.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of splicing events with the fraction of different immune cells and the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeSplicingTypeSplicingGeneSplicingChrSplicingPositionbetaFDRPearsonPPearsonRCorrelationPlotRBPRBPtargetsImmuneGeneImmuneFractionHallMark
chr15:51912124-51915053:+
BLCAEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.47278.6541e-171.3039e-19-0.4395imageNAUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;LARP7;NOP56;NOP58;NUMA1;PRPF8;RANGAP1;RBFOX2;RBM10;RNF219;SLTM;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000138594.11,TMOD3
BLCAEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.47329.6334e-171.1625e-19-0.4400imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184PRKCSHMacrophages_M1GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
chr15:51912124-51915053:+
CESCEERMEXENSG00000196510.8chr12110381751:110381948:110382842:110382960:110387738:110387892:110388511:1103886230.32029.1686e-057.3062e-130.4055imageNAUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DKC1;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;LARP7;NOP56;NOP58;NUMA1;PRPF8;RANGAP1;RBFOX2;RBM10;RNF219;SLTM;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184NAT_cells_regulatory_(Tregs)GSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000138594.11,TMOD3
CESCEAGIRENSG00000205744.5chr196467206:6468118:6468233:6468327-0.39347.6529e-081.9847e-12-0.4002imageNADAR;BCCIP;CELF2;CSTF2T;DGCR8;DKC1;EIF4A3;EIF4G2;ELAVL1;FBL;FUS;FXR1;GTF2F1;HNRNPC;HNRNPL;HNRNPM;HNRNPU;IGF2BP2;LIN28;LIN28B;NOP56;NOP58;PRPF8;SRSF7;TAF15;TARDBP;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1NAT_cells_CD8GSVA_HALLMARK_ALLOGRAFT_REJECTION
chr15:51912124-51915053:+
CESCEERIRENSG00000137965.6chr178659311:78661456:78662703:78662756-0.23191.5509e-035.0438e-12-0.4455imageNEIF4A3;ELAVL1;FBL;FUS;IGF2BP2;IGF2BP3;SRSF1;SRSF9;TAF15;TROVE2;U2AF2IFI44T_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
ENSG00000138594.11,TMOD3
CESCEAGIRENSG00000137965.6chr178659311:78661456:78662703:78662756-0.22911.7921e-036.7194e-12-0.4431imageNADAR;EIF4A3;ELAVL1;FBL;FUS;HNRNPA1;HNRNPL;IGF2BP2;IGF2BP3;MSI1;PTBP1;RBM47;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TROVE2;U2AF2;YTHDC1IFI44T_cells_CD4_memory_activatedGSVA_HALLMARK_MITOTIC_SPINDLE
chr15:51912124-51915053:+
CESCEERIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.43012.0982e-097.5794e-14-0.4204imageNAUH;BCCIP;BUD13;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;EIF4A3;ELAVL1;FAM120A;FBL;FMR1;FUS;FXR2;GTF2F1;HNRNPC;HNRNPK;HNRNPM;IGF2BP2;IGF2BP3;LARP7;NOP56;NOP58;NUMA1;PRPF8;RANGAP1;RBFOX2;RBM10;RNF219;SLTM;SND1;SRSF1;SRSF9;TAF15;TROVE2;U2AF1;U2AF2;UPF1;XRN2;ZNF184PRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000138594.11,TMOD3
CESCEAGIRENSG00000130175.5chr1911449265:11449882:11450428:11450716-0.42253.5819e-091.6986e-13-0.4149imageNACIN1;ADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CAPRIN1;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DHX9;DICER1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RBM6;RNF219;RTCB;SAFB2;SBDS;SF3A3;SF3B4;SLBP;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184PRKCSHMacrophages_M0GSVA_HALLMARK_INTERFERON_ALPHA_RESPONSE
ENSG00000138594.11,TMOD3
COADEAGESENSG00000108100.13chr1035337051:35337207:35483403:35483478:35501500:35501535-0.25481.1448e-026.0066e-13-0.4197imageNACIN1;ADAR;BCCIP;BUD13;CAPRIN1;CELF2;CNBP;CSTF2T;DDX3X;DDX54;DGCR8;DHX9;DICER1;DKC1;EIF4A3;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GTF2F1;HNRNPA1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHDRBS2;KHDRBS3;LARP4B;LARP7;LIN28;LIN28A;LIN28B;MBNL2;MOV10;MSI1;MSI2;NOP56;NOP58;NPM1;PCBP2;PRPF8;PTBP1;PUM2;QKI;RBFOX2;RBM10;RBM47;RC3H1;SF3B4;SLBP;SRSF1;SRSF10;SRSF3;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TIAL1;TNRC6A;TROVE2;U2AF1;U2AF2;UPF1;YTHDC1;YTHDF1;ZC3H7B;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_WNT_BETA_CATENIN_SIGNALING
ENSG00000138594.11,TMOD3
COADEAGA3ENSG00000219481.6chr116567978:16568030:16567178:16567271:16567178:165673510.05884.7355e-022.2777e-130.4698imageNADAR;AIFM1;ALYREF;AUH;BCCIP;BUD13;CELF2;CNBP;CPSF6;CSTF2T;DDX3X;DDX42;DDX54;DGCR8;DICER1;DKC1;EIF4A3;EIF4G2;ELAVL1;ELAVL3;EWSR1;FAM120A;FBL;FMR1;FUS;FXR1;FXR2;GNL3;GTF2F1;HNRNPA1;HNRNPA2B1;HNRNPC;HNRNPD;HNRNPK;HNRNPL;HNRNPM;HNRNPU;HNRNPUL1;IGF2BP1;IGF2BP2;IGF2BP3;ILF3;KHDRBS1;KHSRP;LARP4B;LARP7;LIN28;LIN28A;LIN28B;LSM11;MBNL2;METTL3;MOV10;MSI1;MSI2;NONO;NOP56;NOP58;NPM1;NUMA1;PCBP2;PRPF8;PTBP1;QKI;RANGAP1;RBFOX2;RBM10;RBM22;RBM27;RBM47;RC3H1;RNF219;SAFB2;SBDS;SF3A3;SF3B4;SLTM;SMNDC1;SND1;SRSF1;SRSF10;SRSF7;SRSF9;TAF15;TARDBP;TIA1;TNRC6A;TRA2A;TROVE2;U2AF1;U2AF2;UPF1;XRN2;YTHDC1;YTHDF1;YWHAG;ZNF184NADendritic_cells_activatedGSVA_HALLMARK_SPERMATOGENESIS

More results



Top

5. Enriched editing regions and immune infiltration for TMOD3


all structure

check button Associations of enriched editing regions with immune infiltration.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the fraction of different immune cells according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerTypeIDImmuneCellPRCorrelationPlot
chr15:51912124-51915053:+BLCAEERT_cells_CD4_memory_activated7.7265e-090.2886image
ENSG00000138594.11,TMOD3BLCAEAGT_cells_CD4_memory_activated8.2229e-090.2881image
chr15:51912124-51915053:+BRCAEERT_cells_regulatory_(Tregs)4.5896e-090.1799image
ENSG00000138594.11,TMOD3BRCAEAGT_cells_regulatory_(Tregs)9.6298e-090.1760image
chr15:51912124-51915053:+CESCEERMonocytes1.5496e-030.1851image
ENSG00000138594.11,TMOD3CESCEAGMonocytes1.3316e-030.1876image
chr15:51912124-51915053:+COADEERMacrophages_M11.7856e-050.2588image
ENSG00000138594.11,TMOD3COADEAGT_cells_CD81.0364e-030.1986image
chr15:51912124-51915053:+ESCAEERNK_cells_activated7.0071e-040.2644image
ENSG00000138594.11,TMOD3ESCAEAGNK_cells_activated6.9307e-040.2646image
chr15:51912124-51915053:+GBMEERNK_cells_resting2.6682e-03-0.2485image
ENSG00000138594.11,TMOD3GBMEAGNK_cells_resting2.6682e-03-0.2485image
chr15:51912124-51915053:+HNSCEERMacrophages_M23.3515e-040.1627image
ENSG00000138594.11,TMOD3HNSCEAGMacrophages_M12.7982e-040.1648image
chr15:51912124-51915053:+KICHEERT_cells_CD4_memory_activated2.5992e-030.3675image
ENSG00000138594.11,TMOD3KICHEAGT_cells_CD4_memory_activated2.5992e-030.3675image
chr15:51912124-51915053:+KIRCEERT_cells_regulatory_(Tregs)4.8372e-070.2544image
ENSG00000138594.11,TMOD3KIRCEAGT_cells_regulatory_(Tregs)5.4688e-070.2533image
chr15:51912124-51915053:+KIRPEERT_cells_CD4_memory_resting2.6585e-06-0.2813image
ENSG00000138594.11,TMOD3KIRPEAGT_cells_CD4_memory_resting2.6585e-06-0.2813image
chr15:51912124-51915053:+LAMLEERT_cells_regulatory_(Tregs)4.0144e-030.2461image
ENSG00000138594.11,TMOD3LAMLEAGT_cells_regulatory_(Tregs)3.8531e-030.2454image
chr15:51912124-51915053:+LGGEERT_cells_CD4_naive8.7142e-030.1383image
ENSG00000138594.11,TMOD3LGGEAGT_cells_CD4_naive8.1868e-030.1392image
chr15:51912124-51915053:+LIHCEERT_cells_gamma_delta1.4450e-020.1466image
ENSG00000138594.11,TMOD3LIHCEAGT_cells_gamma_delta1.4450e-020.1466image
chr15:51912124-51915053:+LUADEERT_cells_CD4_memory_resting3.4543e-04-0.1617image
ENSG00000138594.11,TMOD3LUADEAGT_cells_CD4_memory_resting5.1578e-04-0.1569image
chr15:51912124-51915053:+LUSCEERT_cells_CD4_memory_activated1.1405e-040.1774image
ENSG00000138594.11,TMOD3LUSCEAGT_cells_CD4_memory_activated1.1405e-040.1774image
chr15:51912124-51915053:+MESOEERDendritic_cells_activated2.2675e-030.3346image
ENSG00000138594.11,TMOD3MESOEAGDendritic_cells_activated2.2675e-030.3346image
chr15:51912124-51915053:+OVEERT_cells_CD82.9181e-030.1776image
ENSG00000138594.11,TMOD3OVEAGT_cells_CD87.7499e-030.1583image
chr15:51912124-51915053:+PAADEERB_cells_naive2.9021e-03-0.2271image
ENSG00000138594.11,TMOD3PAADEAGB_cells_naive2.9021e-03-0.2271image
chr15:51912124-51915053:+PCPGEERNK_cells_activated1.3481e-040.3515image
ENSG00000138594.11,TMOD3PCPGEAGNK_cells_activated1.3481e-040.3515image
chr15:51912124-51915053:+PRADEERDendritic_cells_resting2.9813e-03-0.1369image
ENSG00000138594.11,TMOD3PRADEAGNK_cells_resting4.4563e-030.1311image
chr15:51912124-51915053:+SARCEERT_cells_CD4_memory_activated5.1122e-030.1784image
ENSG00000138594.11,TMOD3SARCEAGT_cells_CD4_memory_activated5.1122e-030.1784image
chr15:51912124-51915053:+SKCMEERT_cells_CD83.3334e-050.2069image
ENSG00000138594.11,TMOD3SKCMEAGT_cells_CD83.8112e-050.2054image
chr15:51912124-51915053:+STADEERT_cells_CD4_memory_activated3.1210e-030.1547image
chr15:51931974-51933639:+STADEERT_cells_CD4_naive1.2922e-020.5326image
ENSG00000138594.11,TMOD3STADEAGDendritic_cells_activated6.5054e-040.1781image
chr15:51912124-51915053:+TGCTEERMacrophages_M23.8189e-04-0.3204image
ENSG00000138594.11,TMOD3TGCTEAGMacrophages_M23.8189e-04-0.3204image
chr15:51912124-51915053:+THCAEERNeutrophils5.6120e-030.1246image
ENSG00000138594.11,TMOD3THCAEAGNeutrophils5.6120e-030.1246image
chr15:51912124-51915053:+THYMEERMacrophages_M11.2956e-030.3221image
ENSG00000138594.11,TMOD3THYMEAGMast_cells_resting1.1154e-020.2554image
chr15:51912124-51915053:+UCECEERDendritic_cells_resting2.5410e-02-0.1856image
ENSG00000138594.11,TMOD3UCECEAGDendritic_cells_resting2.5410e-02-0.1856image
chr15:51912124-51915053:+UCSEERT_cells_follicular_helper4.5852e-02-0.2837image
ENSG00000138594.11,TMOD3UCSEAGT_cells_follicular_helper4.5688e-02-0.2839image
chr15:51912124-51915053:+UVMEERB_cells_memory1.8123e-020.4030image
ENSG00000138594.11,TMOD3UVMEAGB_cells_memory1.8123e-020.4030image


Top

6. Enriched editing regions and immune gene sets for TMOD3


all structure

check button Correlation of enriched editing regions with epithelial-mesenchymal transition.
* First, the differences of enriched editing regions between Epi and Mes groups (defined by KS-test) were compared (P<0.05 and Informative number >=20).
* Second, the correlations between enriched editing regions and gene set score of HALLMARK_EPITHELIAL_MESENCHYMAL_TRANSITION were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly edited between Epi and Mes group.
ID_eventscancerTypeE2M_PBoxplotCorPCorRCorrelationPlot
chr15:51912124-51915053:+BLCAEER3.5175e-02image6.0488e-070.2507image
ENSG00000138594.11,TMOD3BLCAEAG3.4950e-02image6.0921e-070.2506image
chr15:51912124-51915053:+BRCAEER1.3777e-02image4.6649e-04-0.1080image
ENSG00000138594.11,TMOD3BRCAEAG4.8406e-02image3.6949e-04-0.1098image
chr15:51912124-51915053:+THCAEER4.4686e-02image3.6462e-05-0.1848image
ENSG00000138594.11,TMOD3THCAEAG4.4686e-02image3.6462e-05-0.1848image


Top

check button Correlations of enriched editing regions with hypoxic.
* First, there are four hypoxia scores used in the database. The first three hypoxic scores were calculated on three gene sets of Buffa, Ragnum and Winter based on one previous study (PMID: 32024819). One last hypoxia score was defined on HALLMARK_HYPOXIA by GSVA method.
* Second, the correlations enriched editing regions with the four hypoxic scores were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the EERs/EAGs significantly correlated with all four hypoxia gene set scores. For more results, please go to download page.
ID_eventscancerTypeBuffa_P Buffa_R Ragnum_P Ragnum_R Winter_P Winter_R HALLMARK_P HALLMARK_R CorrelationPlot
chr15:51912124-51915053:+LUADEER1.9137e-040.16844.7368e-030.12794.4462e-020.09122.6551e-030.1360image
ENSG00000138594.11,TMOD3LUADEAG1.9583e-040.16824.4988e-030.12874.3209e-020.09183.2981e-030.1330image
chr15:51912124-51915053:+STADEER3.1959e-050.21641.5283e-030.16585.6873e-040.18002.8184e-020.1152image


Top

check button Associations of enriched editing regions with hallmark gene sets from MSigDB.
* P<0.05 and Informative number >=20.
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the scores of 50 hallmark genesets according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerHallmarkTypeTypePRCorrelationPlot
ENSG00000138594.11,TMOD3BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEAG2.3075e-110.3317image
chr15:51912124-51915053:+BLCAGSVA_HALLMARK_INTERFERON_GAMMA_RESPONSEEER2.3585e-110.3315image
ENSG00000138594.11,TMOD3BRCAGSVA_HALLMARK_UV_RESPONSE_DNEAG2.9286e-19-0.2722image
chr15:51912124-51915053:+BRCAGSVA_HALLMARK_REACTIVE_OXYGEN_SPECIES_PATHWAYEER1.1773e-190.2752image
ENSG00000138594.11,TMOD3CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.1710e-110.3732image
chr15:51912124-51915053:+CESCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.5845e-110.3713image
ENSG00000138594.11,TMOD3CHOLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.9681e-020.4041image
chr15:51912124-51915053:+CHOLGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.9681e-020.4041image
ENSG00000138594.11,TMOD3COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG5.0962e-070.3000image
chr15:51912124-51915053:+COADGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.4659e-090.3510image
chr15:51912124-51915053:+DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEER9.8179e-030.4715image
ENSG00000138594.11,TMOD3DLBCGSVA_HALLMARK_KRAS_SIGNALING_DNEAG9.8179e-030.4715image
chr15:51912124-51915053:+ESCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.4748e-02-0.1919image
chr15:51866172-51866440:+ESCAGSVA_HALLMARK_XENOBIOTIC_METABOLISMEER2.6625e-02-0.3420image
ENSG00000138594.11,TMOD3ESCAGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.1473e-02-0.1988image
ENSG00000138594.11,TMOD3GBMGSVA_HALLMARK_APICAL_JUNCTIONEAG9.9260e-03-0.2142image
chr15:51912124-51915053:+GBMGSVA_HALLMARK_APICAL_JUNCTIONEER9.9260e-03-0.2142image
ENSG00000138594.11,TMOD3HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.0121e-120.3171image
chr15:51912124-51915053:+HNSCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER2.7735e-110.2972image
ENSG00000138594.11,TMOD3KICHGSVA_HALLMARK_KRAS_SIGNALING_DNEAG6.8700e-03-0.3321image
chr15:51912124-51915053:+KICHGSVA_HALLMARK_KRAS_SIGNALING_DNEER6.8700e-03-0.3321image
chr15:51912124-51915053:+KIRCGSVA_HALLMARK_UV_RESPONSE_DNEER2.4447e-12-0.3488image
ENSG00000138594.11,TMOD3KIRCGSVA_HALLMARK_UV_RESPONSE_DNEAG2.5757e-12-0.3484image
chr15:51912124-51915053:+KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEER8.8295e-07-0.2939image
ENSG00000138594.11,TMOD3KIRPGSVA_HALLMARK_MITOTIC_SPINDLEEAG8.8295e-07-0.2939image
chr15:51912124-51915053:+LAMLGSVA_HALLMARK_HEME_METABOLISMEER1.9845e-020.2003image
ENSG00000138594.11,TMOD3LAMLGSVA_HALLMARK_HEME_METABOLISMEAG1.8301e-020.2014image
ENSG00000138594.11,TMOD3LIHCGSVA_HALLMARK_PROTEIN_SECRETIONEAG6.0300e-05-0.2382image
chr15:51912124-51915053:+LIHCGSVA_HALLMARK_PROTEIN_SECRETIONEER6.0300e-05-0.2382image
chr15:51912124-51915053:+LUADGSVA_HALLMARK_MTORC1_SIGNALINGEER8.7743e-090.2572image
ENSG00000138594.11,TMOD3LUADGSVA_HALLMARK_MTORC1_SIGNALINGEAG1.4627e-080.2534image
ENSG00000138594.11,TMOD3LUSCGSVA_HALLMARK_DNA_REPAIREAG4.4754e-040.1616image
chr15:51912124-51915053:+LUSCGSVA_HALLMARK_DNA_REPAIREER4.4754e-040.1616image
chr15:51912124-51915053:+MESOGSVA_HALLMARK_ANDROGEN_RESPONSEEER1.9740e-03-0.3388image
ENSG00000138594.11,TMOD3MESOGSVA_HALLMARK_ANDROGEN_RESPONSEEAG1.9740e-03-0.3388image
chr15:51912124-51915053:+OVGSVA_HALLMARK_DNA_REPAIREER2.2590e-080.3269image
ENSG00000138594.11,TMOD3OVGSVA_HALLMARK_DNA_REPAIREAG7.2849e-080.3139image
chr15:51912124-51915053:+PAADGSVA_HALLMARK_ANDROGEN_RESPONSEEER2.7962e-07-0.3818image
ENSG00000138594.11,TMOD3PAADGSVA_HALLMARK_ANDROGEN_RESPONSEEAG2.7962e-07-0.3818image
chr15:51912124-51915053:+PCPGGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEER4.3760e-030.2662image
ENSG00000138594.11,TMOD3PCPGGSVA_HALLMARK_OXIDATIVE_PHOSPHORYLATIONEAG4.3760e-030.2662image
ENSG00000138594.11,TMOD3PRADGSVA_HALLMARK_PROTEIN_SECRETIONEAG1.1107e-08-0.2599image
chr15:51912124-51915053:+PRADGSVA_HALLMARK_PROTEIN_SECRETIONEER8.4195e-09-0.2620image
ENSG00000138594.11,TMOD3READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG1.4018e-040.3867image
chr15:51912124-51915053:+READGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER1.4018e-040.3867image
ENSG00000138594.11,TMOD3SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG4.3259e-080.3411image
chr15:51912124-51915053:+SARCGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER4.3259e-080.3411image
chr15:51912124-51915053:+SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER6.3033e-090.2866image
ENSG00000138594.11,TMOD3SKCMGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG7.0369e-090.2858image
ENSG00000138594.11,TMOD3STADGSVA_HALLMARK_UV_RESPONSE_UPEAG1.9617e-050.2220image
chr15:51931974-51933639:+STADGSVA_HALLMARK_PANCREAS_BETA_CELLSEER7.1515e-03-0.5686image
chr15:51912124-51915053:+STADGSVA_HALLMARK_UV_RESPONSE_UPEER6.7010e-070.2573image
chr15:51912124-51915053:+TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEER1.2910e-03-0.2916image
ENSG00000138594.11,TMOD3TGCTGSVA_HALLMARK_TGF_BETA_SIGNALINGEAG1.2910e-03-0.2916image
chr15:51912124-51915053:+THCAGSVA_HALLMARK_UV_RESPONSE_DNEER2.5658e-12-0.3083image
ENSG00000138594.11,TMOD3THCAGSVA_HALLMARK_UV_RESPONSE_DNEAG2.5658e-12-0.3083image
chr15:51912124-51915053:+THYMGSVA_HALLMARK_MITOTIC_SPINDLEEER7.8705e-07-0.4769image
ENSG00000138594.11,TMOD3THYMGSVA_HALLMARK_MITOTIC_SPINDLEEAG9.4547e-08-0.5078image
chr15:51912124-51915053:+UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEER3.4344e-050.3368image
ENSG00000138594.11,TMOD3UCECGSVA_HALLMARK_INTERFERON_ALPHA_RESPONSEEAG3.4344e-050.3368image
chr15:51912124-51915053:+UCSGSVA_HALLMARK_UV_RESPONSE_UPEER1.8855e-030.4289image
ENSG00000138594.11,TMOD3UCSGSVA_HALLMARK_UV_RESPONSE_UPEAG1.8655e-030.4293image


Top

7. Enriched editing regions and drugs for TMOD3


all structure

check button Correlations between enriched editing regions and drug sensitivity.
* First, the drug sensitivity (IS50) was estimated on 84 drugs by pRRophetic package.
* Second, the correlations between editing enriched regions and drug sensitivity were analyzed (P<0.05 and Informative number >=20).
* EER: enriched editing region, EAG: EER-associated genes.
* Only shows the most significant correlation result of EERs/EAGs with the IS50 scores of 84 drugs according to correlation coefficient (R). For more results, please go to download page.
ID_eventscancerDrugTypePRCorrelationPlot
ENSG00000138594.11,TMOD3ACCABT.263EAG4.1752e-030.3618image
chr15:51912124-51915053:+ACCABT.263EER4.1752e-030.3618image
chr15:51912124-51915053:+BLCACisplatinEER7.0627e-09-0.2893image
ENSG00000138594.11,TMOD3BLCACisplatinEAG6.8215e-09-0.2896image
ENSG00000138594.11,TMOD3BRCACCT007093EAG2.5940e-120.2139image
chr15:51912124-51915053:+BRCACCT007093EER6.2816e-130.2199image
ENSG00000138594.11,TMOD3CESCBAY.61.3606EAG1.0679e-060.2819image
chr15:51912124-51915053:+CESCBAY.61.3606EER3.3296e-070.2943image
chr15:51912124-51915053:+COADCI.1040EER1.5064e-05-0.2610image
ENSG00000138594.11,TMOD3COADCI.1040EAG3.7211e-04-0.2151image
ENSG00000138594.11,TMOD3DLBCAZD6244EAG1.8368e-02-0.4350image
chr15:51912124-51915053:+DLBCAZD6244EER1.8368e-02-0.4350image
chr15:51866172-51866440:+ESCAJNK.Inhibitor.VIIIEER1.0815e-02-0.3894image
chr15:51912124-51915053:+ESCAAMG.706EER4.2886e-03-0.2247image
ENSG00000138594.11,TMOD3ESCAAMG.706EAG2.5596e-03-0.2369image
ENSG00000138594.11,TMOD3GBMLFM.A13EAG1.0667e-030.2700image
chr15:51912124-51915053:+GBMLFM.A13EER1.0667e-030.2700image
ENSG00000138594.11,TMOD3HNSCBMS.536924EAG2.5290e-14-0.3377image
chr15:51912124-51915053:+HNSCBMS.536924EER5.4269e-16-0.3577image
chr15:51912124-51915053:+KICHCisplatinEER4.8870e-08-0.6154image
ENSG00000138594.11,TMOD3KICHCisplatinEAG4.8870e-08-0.6154image
chr15:51912124-51915053:+KIRCAZD6244EER5.0870e-12-0.3439image
ENSG00000138594.11,TMOD3KIRCAZD6244EAG8.4860e-12-0.3405image
chr15:51912124-51915053:+KIRPCCT007093EER1.7263e-120.4120image
ENSG00000138594.11,TMOD3KIRPCCT007093EAG1.7263e-120.4120image
ENSG00000138594.11,TMOD3LAMLJNK.9LEAG6.9869e-04-0.2862image
chr15:51912124-51915053:+LAMLJNK.9LEER1.2151e-03-0.2756image
chr15:51912124-51915053:+LGGEHT.1864EER2.2189e-02-0.1207image
ENSG00000138594.11,TMOD3LGGEHT.1864EAG2.4996e-02-0.1181image
ENSG00000138594.11,TMOD3LIHCBMS.754807EAG4.9972e-050.2416image
chr15:51912124-51915053:+LIHCBMS.754807EER4.9972e-050.2416image
ENSG00000138594.11,TMOD3LUADBMS.509744EAG4.5369e-05-0.1839image
chr15:51912124-51915053:+LUADBMS.509744EER3.3037e-05-0.1871image
chr15:51912124-51915053:+LUSCAP.24534EER6.3614e-040.1573image
ENSG00000138594.11,TMOD3LUSCAP.24534EAG6.3614e-040.1573image
chr15:51912124-51915053:+MESOBMS.536924EER3.8855e-03-0.3174image
ENSG00000138594.11,TMOD3MESOBMS.536924EAG3.8855e-03-0.3174image
chr15:51912124-51915053:+OVA.770041EER1.6713e-06-0.2822image
ENSG00000138594.11,TMOD3OVA.770041EAG1.1237e-05-0.2582image
chr15:51912124-51915053:+PAADFH535EER1.5610e-04-0.2877image
ENSG00000138594.11,TMOD3PAADFH535EAG1.5610e-04-0.2877image
chr15:51912124-51915053:+PCPGGW.441756EER5.8347e-03-0.2578image
ENSG00000138594.11,TMOD3PCPGGW.441756EAG5.8347e-03-0.2578image
ENSG00000138594.11,TMOD3PRADBAY.61.3606EAG2.4611e-060.2156image
chr15:51912124-51915053:+PRADBAY.61.3606EER1.2620e-060.2216image
chr15:51912124-51915053:+READBicalutamideEER6.5541e-030.2815image
ENSG00000138594.11,TMOD3READBicalutamideEAG6.5541e-030.2815image
chr15:51912124-51915053:+SARCAG.014699EER1.6325e-060.3007image
ENSG00000138594.11,TMOD3SARCAG.014699EAG1.6325e-060.3007image
chr15:51912124-51915053:+SKCMCI.1040EER7.8870e-07-0.2451image
ENSG00000138594.11,TMOD3SKCMCI.1040EAG8.4326e-07-0.2445image
ENSG00000138594.11,TMOD3STADGW843682XEAG1.1022e-04-0.2016image
chr15:51912124-51915053:+STADGW843682XEER1.6029e-04-0.1968image
chr15:51931974-51933639:+STADEpothilone.BEER1.0545e-03-0.6630image
ENSG00000138594.11,TMOD3TGCTKIN001.135EAG1.0148e-030.2976image
chr15:51912124-51915053:+TGCTKIN001.135EER1.0148e-030.2976image
chr15:51912124-51915053:+THCAEmbelinEER1.6278e-120.3110image
ENSG00000138594.11,TMOD3THCAEmbelinEAG1.6278e-120.3110image
chr15:51912124-51915053:+THYMABT.263EER5.3569e-070.4832image
ENSG00000138594.11,TMOD3THYMBAY.61.3606EAG4.4425e-100.5784image
chr15:51912124-51915053:+UCECJNK.Inhibitor.VIIIEER9.7471e-05-0.3179image
ENSG00000138594.11,TMOD3UCECJNK.Inhibitor.VIIIEAG9.7471e-05-0.3179image
ENSG00000138594.11,TMOD3UCSBortezomibEAG1.5056e-03-0.4371image
chr15:51912124-51915053:+UCSBortezomibEER1.5036e-03-0.4371image
chr15:51912124-51915053:+UVMCI.1040EER1.5681e-02-0.4112image
ENSG00000138594.11,TMOD3UVMCI.1040EAG1.5681e-02-0.4112image


Top

check button EAGs targeted by drugs from DrugBank database.
* EAG: EER-associated genes.
EERENSTUniprotIDDrugBankIDDrugDrugType